Pfizer sales miss as breast cancer drug disappoints

(Reuters) - Leading U.S. drugmaker Pfizer Inc racked up its biggest miss on sales in a year in the first quarter, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz.

Pfizer sales miss as breast cancer drug disappoints
Read More


Bagikan Berita Ini